DeCure's autonomous Immuno AI scientist is researching a drug-repurposing hypothesis for mixed connective tissue disease — screening already-approved drugs against its 41-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleMixed connective tissue disease maps to a 41-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for mixed connective tissue disease is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
prostaglandin I2 synthase (PTGIS) — PTGIS is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet bogdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 3B6H · 1.62 Å · ligand octyl beta-D-glucopyranoside (BOG). Experimental structure, not a prediction.
What the evidence adds up to
The abstracts provided contain no original clinical data on mixed connective tissue disease. A 1965 textbook and a 1996 textbook are mentioned but not summarised. A 1999 review notes that treatment of connective tissue disease patients is made difficult by potentially severe medication toxicity, and that there is extensive overlap between disease manifestations and adverse drug reactions. The review discusses monitoring of disease modifying antirheumatic drugs but gives no specific outcomes or numbers. A 2021 abstract on connective tissue dysplasia syndrome is about genetically determined conditions, not mixed connective tissue disease. A 2017 article describes a single clinical case and reviews literature on diagnostic criteria and treatment principles, but provides no numerical results, response rates, or survival data.
No concrete numbers for survival, response rates, or sample sizes are reported in any of these abstracts. There is no mention of any specific drug being tested or repurposed for mixed connective tissue disease. The 1999 review only warns about toxicity and monitoring of existing antirheumatic drugs in general.
What is still missing is any original clinical trial data, any randomised controlled trial, any patient cohort with reported outcomes, and any evidence of drug efficacy specific to mixed connective tissue disease. The field lacks funding for dedicated trials, clear patient stratification criteria, and prospective studies that measure response or survival.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Physical Therapy · 1967 · 0 citations
Book Reviews
AbstractJournal Article Book Reviews Get access Pathology of the Connective Tissue Diseases. By D. L. Gardner, Williams & Wilkins Company, Baltimore, 1965. Cloth, 456 pp., illus., $19.50. Jack Wickstrom, M.D. Jack Wickstrom, M.D. Search for other works by this author on: Oxford Academic Google Scholar Physical Therapy, Volume 47, Issue 4, April 1967, Page 337, https://doi.org/10.1093/ptj/47.4.337 Published: 01 April 1967
AbstractEd Jill J F Belch, R B Zurier Chapman and Hall, £79, pp 392 ISBN 0 412 48620 2
How can connective tissue diseases be characterised? Most doctors consider the hallmark to be the presence of immunological changes in patients with systemic symptoms and multivisceral involvement. Connective Tissue Diseases covers most of this heterogeneous group of disorders, although it omits rare diseases such as relapsing polychondritis or hypereosinophilic …
Seminars in Respiratory and Critical Care Medicine · 1999 · 0 citations
Medication Toxicity in the Connective Tissue Diseases
AbstractTreatment of connective tissue disease patients is made difficult by the potentially severe toxicity associated with the medications used. Further, there is extensive overlap between disease-associated manifestations and the adverse drug reactions. The adverse drug reactions mainly affect the dermatological, gastrointestinal, hematologic, reproductive, and pulmonary systems. This review will outline the spectrum of adverse drug reactions in these systems and will review specifics for the appropriate use and monitoring of disease modifying antirheumatic drugs for the treatment of connective tissue diseases. It includes discussion of the role of history, blood chemistries, pulmonary function tests, radiological and invasive procedures in the monitoring of these medications. Close attention was paid to published guidelines when available and to what is known about the pathophysiology in the other cases with recommendations designed to minimize toxicity and cost.
The American Journal of Medical Sciences and Pharmaceutical Research · 2021 · 0 citations · open access
Clinical Course In Upper Gastrointestinal Patients With Connective Tissue Dysplasia Syndrome
AbstractConnective tissue dysplasias (CTDs) are genetically determined conditions characterised by defects in fibrous structures and connective tissue basic substance, leading to organ and system malformations, having a progressive course, defining features of associated pathology, as well as pharmacokinetics and pharmacodynamics of drugs.
Medicine of Ukraine · 2017 · 0 citations · open access
Mixed connective tissue disease in the practice of a family doctor
AbstractThis article describes the clinical case of a mixed connective tissue disease in family doctor’s practice. A review of literature on etiology, pathogenesis, clinics, diagnostic criteria and treatment principles, as well as a prognosis for life in mixed connective tissue disease in the practice of a family doctor are presented.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
